Hyperplasia of Mammary Glands
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Tasly PharmaceuticalChina - Tianjin
1 program1
Xiang Ju Ru Pi Ning capsule PlaceboPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Tasly PharmaceuticalXiang Ju Ru Pi Ning capsule Placebo
Clinical Trials (1)
Total enrollment: 430 patients across 1 trials
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Start: Apr 2024Est. completion: Jul 2026430 patients
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 430 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.